Lupin Launches FDA-Approved Diabetes Drug in US Market with Multiple Dosage Strengths

Lupin Limited has officially launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States following approval from the U.S. FDA. The pharmaceutical company announced this significant milestone, marking another important addition to its diabetes treatment portfolio in the American market.

FDA Approval and Product Specifications

The launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) from the U.S. FDA, which confirmed the product as bioequivalent to Xigduo XR for approved labeling indications. The company has introduced the combination therapy in multiple dosage strengths to meet diverse patient needs.

Product Details:	Specifications
Active Ingredients:	Dapagliflozin and Metformin Hydrochloride
Formulation:	Extended-Release Tablets
Dosage Strengths:	5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg
Reference Product:	Bioequivalent to Xigduo XR
Regulatory Status:	FDA-Approved ANDA

Market Expansion Strategy

This product launch reinforces Lupin's commitment to expanding its presence in the US pharmaceutical market. The introduction of FDA-approved diabetes treatment medications aligns with the company's strategy to strengthen its portfolio in key therapeutic areas where there is significant patient demand.

Therapeutic Significance

The combination of Dapagliflozin and Metformin Hydrochloride in an extended-release formulation offers healthcare providers and patients an additional treatment option in diabetes management. Extended-release formulations typically provide improved patient compliance through reduced dosing frequency compared to immediate-release alternatives.

Company Profile

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets worldwide. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals across multiple therapy areas including anti-diabetic treatments.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.04%	-2.44%	-1.15%	+17.04%	+8.65%	+110.95%

Lupin has received a Form 483 from the US Food and Drug Administration (USFDA) containing three observations for its manufacturing facility in Somerset, New Jersey, USA. The pharmaceutical company disclosed this regulatory development through an official communication to stock exchanges, highlighting compliance matters that require attention at one of its key US manufacturing sites.

Inspection Timeline and Details

The USFDA conducted its inspection of Lupin's Somerset, New Jersey manufacturing facility from April 13, 2026 to April 17, 2026. Following the completion of the inspection, the regulatory authority issued Form 483 documenting three specific observations that need to be addressed by the company.

Parameter:	Details
Facility Location:	Somerset, New Jersey, USA
Inspection Period:	April 13-17, 2026
Regulatory Authority:	USFDA
Document Type:	Form 483
Number of Observations:	Three

Regulatory Disclosure Requirements

Lupin made this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the disclosure with both the National Stock Exchange of India Limited and BSE Limited, ensuring transparency with stakeholders regarding this regulatory matter.

Company Response and Commitment

Lupin has committed to addressing the observations identified during the inspection and will respond to the USFDA within the stipulated timeframe. The company emphasized its commitment to maintaining compliance with current Good Manufacturing Practice (cGMP) standards across all its facilities. This response demonstrates the company's proactive approach to regulatory compliance and quality assurance.

Understanding Form 483 Impact

Form 483 serves as an official communication tool between the FDA and pharmaceutical companies, outlining observations where inspectors believe the facility may not be in full compliance with FDA regulations or cGMP standards. The Somerset facility represents an important part of Lupin's manufacturing infrastructure in the United States, serving one of the largest pharmaceutical markets globally.